Testing combinations of drugs for tuberculosis in mice
Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice
This study is looking at different combinations of medications to find the best way to treat tuberculosis, especially for people who also have HIV, using mice to help guide future treatments for humans.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Colorado State University NIH-funded |
| Lab location | 1 site (Fort Collins, United States) |
| Project ID | NIH-11192197 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of various drug combinations against Mycobacterium tuberculosis (MTB) using a mouse model. The approach involves testing these combinations to identify the most effective treatments that could eventually be developed for human use. By utilizing preclinical models, the research aims to gather data that can support the development of new therapies for tuberculosis, particularly in the context of co-infections with HIV. The findings could lead to advancements in treatment protocols for patients suffering from these diseases.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research would be individuals diagnosed with tuberculosis, especially those who may also be co-infected with HIV.
Not a fit: Patients with drug-resistant tuberculosis or those who do not have access to standard tuberculosis treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for tuberculosis, potentially improving outcomes for patients with this disease.
How similar studies have performed: Other research has shown success in using drug combinations to treat tuberculosis, indicating that this approach has potential for further advancements.
Where this research is happening
Fort Collins, United States
- Colorado State University — Fort Collins, United States (Active)
Researchers
- Principal investigator: Slayden, Richard — Colorado State University
- Study coordinator: Slayden, Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.